Sildenafil Citrate Market Analysis

  • Report ID: 2582
  • Published Date: Sep 30, 2025
  • Report Format: PDF, PPT

Sildenafil Citrate Market Segmentation:

Type Segment Analysis

The generic segment leads the type segment in the sildenafil citrate market and is expected to hold 95% of type-based revenue share by 2035. This is the direct result of patent loss, which has made it possible for mass production. Payers such as Medicare and Medicaid highly prefer low-cost generic drugs in their formulary arrangements. The U.S. FDA’s Orange Book has a approved list of generic manufacturers, which ensures intense price competition and solidifying generic sildenafil's position. Further, this makes a default choice for prescriptions and reimbursements, making branded versions a niche segment.

Patient Type Segment Analysis

The adult male sub-segment commands the largest share in the sildenafil citrate market. This dominance is driven by the primary indication for erectile dysfunction, which is prevalent in this demographic. As per the NLM study in January 2024, males aged 40 have mostly had erectile dysfunction. Conditions like diabetes and cardiovascular disease with increasing age, are the primary reasons for expanding the addressable patient pool. This trend underscores the sustained demand for sildenafil citrate, particularly among aging male populations with rising comorbidities.

Dosage Form Segment Analysis

Tablets are dominating the dosage form segment in the sildenafil citrate market and is propelled owing to their efficiency in manufacturing, stability, and convenience in patient usage. The widespread approvals of generic tablet formats by regulatory agencies such as the FDA have established them as market leaders. The AHA Journals in May 2024 have shown that the clinical basis for sildenafil's approval for pulmonary arterial hypertension (PAH) was provided by a landmark trial of 385 patients who were randomized to take 5 mg, 20 mg, or 80 mg tablets three times a day. This strong clinical and regulatory foundation continues to reinforce tablets as the preferred and most trusted dosage form in the market.

Our in-depth analysis of the sildenafil citrate market includes the following segments:

Segment

Subsegments

Application

  • Erectile Dysfunction (ED)
  • Adult Male
  • Pulmonary Arterial Hypertension (PAH)
  • Adult Male
  • Pediatric (PAH-specific)

Dosage Form

  • Tablets
  • Orally Disintegrating Tablets (ODTs)
  • Oral Solutions

Distribution Channel

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

Type

  • Generic
  • Tablets
  • Orally Disintegrating Tablets (ODTs)
  • Oral Solutions
  • Branded
  • Tablets
  • Orally Disintegrating Tablets (ODTs)
  • Oral Solutions

Patient Type

  • Adult Male
  • Pediatric (PAH-specific)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of sildenafil citrate is evaluated at USD 3.9 billion.

Sildenafil Citrate Market size was valued at USD 3.9 billion in 2025 and is projected to reach USD 6.7 billion by the end of 2035, rising at a CAGR of 5.7% during the forecast period, i.e., 2026 to 2035.

North America industry is anticipated to capture a significant share of 40.6% by 2035, attributable to the substantial consumer base and insurance coverage offered by public healthcare systems.

Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Zydus Cadila, Sandoz (Novartis), Bayer AG, Eli Lilly and Company, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Hetero Drugs Ltd., Ajanta Pharma Ltd., Hikma, Pharmaceuticals, Centurion Laboratories, Yabang Pharma.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos